KBI Biopharma vs Pharmaron: CDMO Comparison
How does KBI Biopharma compare to Pharmaron?
As of Nov 2026, KBI Biopharma: 2 FDA inspections (including 0 NAI, 2 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 84.1. Pharmaron: 5 FDA inspections (including 4 NAI, 1 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 86.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of KBI Biopharma and Pharmaron on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Pharmaron has more FDA inspections on record (5 vs 2) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
Across the cross-modality scorecard, Pharmaron carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: KBI Biopharma vs Pharmaron
How does KBI Biopharma compare to Pharmaron?
On CDMO Signal's composite Signal Score, KBI Biopharma is 84/100 and Pharmaron is 87/100; KBI Biopharma has 2 FDA inspections on record vs 5 for Pharmaron; European coverage is 1 active EMA+MHRA certificate for KBI Biopharma vs 1 for Pharmaron. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, KBI Biopharma or Pharmaron?
Both KBI Biopharma and Pharmaron maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. KBI Biopharma has 2 FDA inspections on record; Pharmaron has 5.
How do KBI Biopharma and Pharmaron compare on European GMP coverage?
KBI Biopharma holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Pharmaron holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
KBI Biopharma carries a Signal Score of 84/100 and Pharmaron carries 87/100 — essentially tied for Pharmaron. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →